acpronАкадемия Практической ОнкологииAcademy for Practical Oncology3033-90733033-9421ООО "Издательский дом "МедИНК"10.63769/3033-9073-2026-1-2-62-69acpron-18Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESРак и воспалениеCancer and inflammationhttps://orcid.org/0000-0001-6396-4948АшрафянЛ. А.AshrafyanL. A.

Ашрафян Лев Андреевич, д-р мед. наук, профессор

Москва

 Lev A. Ashrafyan, MD, Dr. Sci. (Medicine), Professor

Moscow

ashrafyan_l_a@staff.sechenov.ruНациональный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В. И. КулаковаРоссияNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after acad. V. I. KulakovaRussian Federation202602092026126269Copyright © Ашрафян Л.А., 20262026Ашрафян Л.А.Ashrafyan L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.apo-j.ru/jour/article/view/18

Воспаление влияет на все этапы развития и прогрессии опухоли, а также на терапевтический ответ. Только путем тщательного исследования каждого аспекта биологии злокачественного процесса мы можем добиваться реальных достижений в борьбе с раком. Комбинация противовоспалительных подходов, ориентированных на микросреду опухоли, должна сочетаться с использованием более сложных и селективно уничтожающих опухоль препаратов. Будущее противораковой терапии стоит за препаратами, нацеленными на проканцерогенное воспаление.

Inflammation influences all stages of tumor development and progression, as well as therapeutic response. Only through careful study of every aspect of the biology of the malignant process can we make real advances in the fight against cancer. A combination of anti-inflammatory approaches targeting the tumor microenvironment should be combined with the use of more complex and selective tumor-killing drugs. The future of anticancer therapy lies in drugs targeting procarcinogenic inflammation.

раквоспалениеонкогенезпротивораковая терапиямикросредамикроокружениепроканцерогенное воспалениесистемная универсальная организация ответных реакцийзащитная реакцияпатогеннормальная воспалительная реакцияcancerinflammationtumorigenesisanticancer therapymicroenvironmentmicroenvironmentprocarcinogenic inflammationsystemic universal organization of responsesdefensive reactionpathogennormal inflammatory responseReferencesДильман В.М. Четыре модели медицины. 1987.Dilman V.M. Four models of medicine. 1987. (In Russ.).Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436–44. DOI: 10.1038/nature07205Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436–44. DOI: 10.1038/nature07205Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010;140(6):771–6. DOI: 10.1016/j.cell.2010.03.006Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010;140(6):771–6. DOI: 10.1016/j.cell.2010.03.006Rocha e Silva M. A brief survey of the history of inflammation. Agents Actions 1978;8(1–2):45–9. DOI: 10.1007/BF01972401Rocha e Silva M. A brief survey of the history of inflammation. Agents Actions 1978;8(1–2):45–9. DOI: 10.1007/BF01972401Zhang K., Shen X., Wu J. et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 2006;124(3):587–99. DOI: 10.1016/j.cell.2005.11.040Zhang K., Shen X., Wu J. et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 2006;124(3):587–99. DOI: 10.1016/j.cell.2005.11.040Zhang K., Kaufman R.J. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008;454(7203):455–62. DOI: 10.1038/nature07203Zhang K., Kaufman R.J. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008;454(7203):455–62. DOI: 10.1038/nature07203Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008;8(12):923–34. DOI: 10.1038/nri2449Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008;8(12):923–34. DOI: 10.1038/nri2449Kawai T., Akira S. TLR signaling. Cell Death Diff 2006;13(5): 816–25. DOI: 10.1038/sj.cdd.4401850Kawai T., Akira S. TLR signaling. Cell Death Diff 2006;13(5): 816–25. DOI: 10.1038/sj.cdd.4401850Schroder K., Tschopp J. The inflammasomes. Cell 2010;140(6):821–32. DOI: 10.1016/j.cell.2010.01.040Schroder K., Tschopp J. The inflammasomes. Cell 2010;140(6):821–32. DOI: 10.1016/j.cell.2010.01.040Majno G. The healing hand: man and wound in the ancient world. Cambridge, Mass: Harvard University Press, 1975.Majno G. The healing hand: man and wound in the ancient world. Cambridge, Mass: Harvard University Press, 1975.American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43(9):1905–15. DOI: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-PAmerican College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43(9):1905–15. DOI: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-PFalkowski P.G., Katz M.E., Milligan A.J. et al. The rise of oxygen over the past 205 million years and the evolution of large placental mammals. Science 2005;309(5744):2202–4. DOI: 10.1126/science.1116047Falkowski P.G., Katz M.E., Milligan A.J. et al. The rise of oxygen over the past 205 million years and the evolution of large placental mammals. Science 2005;309(5744):2202–4. DOI: 10.1126/science.1116047Falkowski P.G. Tracing oxygen’s imprint on earth’s metabolic evolution. Science 2006;311(5768):1724–5. DOI: 10.1126/science.1125937Falkowski P.G. Tracing oxygen’s imprint on earth’s metabolic evolution. Science 2006;311(5768):1724–5. DOI: 10.1126/science.1125937Wynn T.A. IL-13 effector functions. Annu Rev Immunol 2003; 21:425–56. DOI: 10.1146/annurev.immunol.21.120601.141142Wynn T.A. IL-13 effector functions. Annu Rev Immunol 2003; 21:425–56. DOI: 10.1146/annurev.immunol.21.120601.141142Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448–54. DOI: 10.1056/NEJM199902113400607Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448–54. DOI: 10.1056/NEJM199902113400607Kumar V., Abbas A.K., Fausto N. et al. Pathologic basis of disease. 7th. Philadelphia: Elsevier Saunders, 2005.Kumar V., Abbas A.K., Fausto N. et al. Pathologic basis of disease. 7th. Philadelphia: Elsevier Saunders, 2005.Trinchieri G. Cancer and inflammation: An old intuition with rapidly evolving new concepts. Annu Rev Immunol.2012; 30:677–706. DOI: 10.1146/annurev-immunol-020711-075008Trinchieri G. Cancer and inflammation: An old intuition with rapidly evolving new concepts. Annu Rev Immunol.2012; 30:677–706. DOI: 10.1146/annurev-immunol-020711-075008Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454(7203):428–35. DOI: 10.1038/nature07201Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454(7203):428–35. DOI: 10.1038/nature07201Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(Suppl 4): S1–14. DOI: 10.1097/00005344-199322004-00002Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(Suppl 4): S1–14. DOI: 10.1097/00005344-199322004-00002Hedges S.B., Blair J.E., Venturi M.L., Shoe JL. A molecular timescale of eukaryote evolution and the rise of complex multicellular life. BMC Evol Biol 2004;4:2. DOI: 10.1186/1471-2148-4-2Hedges S.B., Blair J.E., Venturi M.L., Shoe JL. A molecular timescale of eukaryote evolution and the rise of complex multicellular life. BMC Evol Biol 2004;4:2. DOI: 10.1186/1471-2148-4-2Maiuri A.R., O’Hagan H.M. Interplay between inflammation and epigenetic changes in cancer. Prog Mol Biol Transl Sci 2016;144:69–117. DOI: 10.1016/bs.pmbts.2016.09.002Maiuri A.R., O’Hagan H.M. Interplay between inflammation and epigenetic changes in cancer. Prog Mol Biol Transl Sci 2016;144:69–117. DOI: 10.1016/bs.pmbts.2016.09.002Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat Rev Cancer 2003;3:276–85. DOI: 10.1038/nrc1046Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat Rev Cancer 2003;3:276–85. DOI: 10.1038/nrc1046Okazaki I.M., Kotani A., Honjo T. Role of AID in tumorigenesis. Adv Immunol 2007;94:245–73. DOI: 10.1016/S0065-2776(06)94008-5Okazaki I.M., Kotani A., Honjo T. Role of AID in tumorigenesis. Adv Immunol 2007;94:245–73. DOI: 10.1016/S0065-2776(06)94008-5DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010;29:309–16. DOI: 10.1007/s10555-010-9223-6DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010;29:309–16. DOI: 10.1007/s10555-010-9223-6Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883–99. DOI: 10.1016/j.cell.2010.01.025Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883–99. DOI: 10.1016/j.cell.2010.01.025Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141(1):39–51. DOI: 10.1016/j.cell.2010.03.01Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141(1):39–51. DOI: 10.1016/j.cell.2010.03.01Colotta F., Allavena P., Sica A. et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073–81. DOI: 10.1093/carcin/bgp127Colotta F., Allavena P., Sica A. et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073–81. DOI: 10.1093/carcin/bgp127Karnoub A.E., Weinberg R.A. Chemokine networks and breast cancer metastasis. Breast Dis 2006;26:75–85. DOI: 10.3233/bd-2007-26107Karnoub A.E., Weinberg R.A. Chemokine networks and breast cancer metastasis. Breast Dis 2006;26:75–85. DOI: 10.3233/bd-2007-26107De Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6(1):24–37. DOI: 10.1038/nrc1782De Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6(1):24–37. DOI: 10.1038/nrc1782Soucek L., Lawlor E.R., Soto D. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13(10):1211–8. DOI: 10.1038/nm1649Soucek L., Lawlor E.R., Soto D. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13(10):1211–8. DOI: 10.1038/nm1649Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6(5):447–58. DOI: 10.1016/j.ccr.2004.09.028Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6(5):447–58. DOI: 10.1016/j.ccr.2004.09.028Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45. DOI: 10.1016/S0140-6736(00)04046-0Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45. DOI: 10.1016/S0140-6736(00)04046-0Vakkila J., Lotze M.T. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4(8):641–8. DOI: 10.1038/nri1415Vakkila J., Lotze M.T. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4(8):641–8. DOI: 10.1038/nri1415Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431–6. DOI: 10.1038/nature04870Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431–6. DOI: 10.1038/nature04870Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315(26):1650–9. DOI: 10.1056/NEJM198612253152606Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315(26):1650–9. DOI: 10.1056/NEJM198612253152606Zong W.X., Thompson C.B. Necrotic death as a cell fate. Genes Dev 2006;20(1):1–15. DOI: 10.1101/gad.1376506Zong W.X., Thompson C.B. Necrotic death as a cell fate. Genes Dev 2006;20(1):1–15. DOI: 10.1101/gad.1376506Retsky M., Demicheli R., Hrushesky W.J.M. et al. Reduction of breast cancer relapses with perioperative non-steroidal antiinflammatory drugs: new findings and a review. Curr Med Chemistry 2013;20(33):4163–76. DOI: 10.2174/09298673113209990250Retsky M., Demicheli R., Hrushesky W.J.M. et al. Reduction of breast cancer relapses with perioperative non-steroidal antiinflammatory drugs: new findings and a review. Curr Med Chemistry 2013;20(33):4163–76. DOI: 10.2174/09298673113209990250Bishoy F. Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol 2012:2:68. DOI: 10.3389/fonc.2012.00068Bishoy F. Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol 2012:2:68. DOI: 10.3389/fonc.2012.00068Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117(5):1175–83. DOI: 10.1172/JCI31537Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117(5):1175–83. DOI: 10.1172/JCI31537Becker C., Fantini M.C., Schramm C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491–501. DOI: 10.1016/j.immuni.2004.07.020Becker C., Fantini M.C., Schramm C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491–501. DOI: 10.1016/j.immuni.2004.07.020Allan A.L., Vantyghem S.A., Tuck A.B., Chambers A.F. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Disease 2006;26(1):87–98. DOI: 10.3233/bd-2007-26108Allan A.L., Vantyghem S.A., Tuck A.B., Chambers A.F. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Disease 2006;26(1):87–98. DOI: 10.3233/bd-2007-26108

The authors declare that there are no conflicts of interest present.